Organism Attribute – Page 3

Pulmonary Hypertension (PH), Interstitial Lung Disease (ILD), Pulmonary Arterial Hypertension (PAH), Clinical Trials, Emerging Therapies, Pathogenesis, Phenotypes, Diagnostic Tools

FDA Delays Approval of Zealand Pharma’s Dasiglucagon for Congenital Hyperinsulinism Due to Third-Party Manufacturing Issues

11 months ago talkbio0Tagged Complete, Congenital MeSH qualifier, dasiglucagon, Hyperinsulinism, issues, Response process, Third, third-party, United States Food and Drug Administration, Zealand Pharma

Zealand Pharma, dasiglucagon, congenital hyperinsulinism, FDA, Complete Response Letter, third-party manufacturing issues

Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma

11 months ago talkbio0Tagged Antibodies, Bispecific, Combined, EMD, Extramedullary Disease in Plasma Cell Myeloma, Frequency of Responses, Refractory Plasma Cell Myeloma, Relapsing course, Response process, Talquetamab, TALVEY, Teclistamab, TECVAYLI

TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses

Triple Threat: 50% of Women Delay or Skip Medical Care Due to Affordability, Access, and Negative Experiences

12 months ago talkbio0Tagged Access, Affordability, barriers, Delayed medical care, disparities, Experience, Gender, Health care facility, Healthcare equity, issues, Negative, Women 's healthcare

Women’s healthcare, Delayed medical care, Affordability issues, Access barriers, Negative healthcare experiences, Gender disparities in healthcare, Healthcare equity

FDA Raises Concerns Over Inappropriate Use of Iterum’s Antibiotic Ahead of Advisory Committee Meeting

1 year ago talkbio0Tagged Advisory Committees, Antibiotic Resistance, Microbial, etzadroxil/probenecid, Iterum, sulopenem, United States Food and Drug Administration, Urinary tract infection, uUTIs

Iterum Therapeutics, FDA, antibiotic resistance, sulopenem etzadroxil/probenecid, uncomplicated urinary tract infections (uUTIs), advisory committee meeting

Women Breaking Barriers in Drug Development: Celebrating Leadership and Innovation

1 year ago talkbio0Tagged Drug Development, Drug Industry, equity, Gender, innovation, Leadership, Scanning Transmission Electron Microscopy Procedures, Woman

Women in drug development, gender equity, STEM, pharmaceutical industry, leadership, innovation

NewAmsterdam’s Obicetrapib Hits Primary Endpoint in Phase III HeFH Study, but Falls Short of Expectations

1 year ago talkbio0Tagged Cardiovascular Diseases, CETP protein, human, Familial hypercholesterolemia - heterozygous, Heterozygote, High Density Lipoprotein Cholesterol, Hypercholesterolemia, Familial, Inhibitor, LDL Cholesterol Lipoproteins, NewAmsterdam Pharma, Obicetrapib, Phase 3 Clinical Trials

NewAmsterdam Pharma, Obicetrapib, CETP Inhibitor, Phase III Trial, Heterozygous Familial Hypercholesterolemia (HeFH), LDL Cholesterol, HDL Cholesterol, Cardiovascular Disease